Relmada Therapeutics (RLMD) Long-Term Deferred Tax (2013)

Relmada Therapeutics' (RLMD) quarterly Long-Term Deferred Tax came in at $48015.0 in Q3 2013.

Relmada Therapeutics (RLMD) Long-Term Deferred Tax (2013) Analysis & Trends

Relmada Therapeutics (RLMD) has 1 years of Long-Term Deferred Tax data on file, last reported at $48015.0 in Q3 2013.

On a quarterly basis, Long-Term Deferred Tax changed N/A year-over-year to $48015.0 in Q3 2013; TTM through Aug 2013 was $48015.0, a N/A change from a year earlier, with the FY2013 full-year figure at $48015.0, changed N/A from the prior year.
Long-Term Deferred Tax for Q3 2013 stood at $48015.0.
Over the last five years, Long-Term Deferred Tax for RLMD reached as high as $48015.0 in Q3 2013 and fell as low as $48015.0 in Q3 2013.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Relmada Therapeutics	205.29 Mn	205.29 Mn	-

Historic Data

Download Data

Date	Value
Aug 31, 2013	48,015.00